stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) EBITDA
Erasca, Inc.'s EBITDA for fiscal 2025 was −$142.9M, compared with −$185.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$302.6M. Over the past ten years it has ranged from −$245.8M (fiscal 2022) to −$13.0M (fiscal 2019); the current reading is higher than 57% of that period. Erasca, Inc. ranks 550th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$142.9M | — |
| FY2024 | −$185.4M | — |
| FY2023 | −$144.7M | — |
| FY2022 | −$245.8M | — |
| FY2021 | −$123.9M | — |
| FY2020 | −$108.8M | — |
| FY2019 | −$13.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$47.4M | — |
| Mar 2026 | −$187.9M | — |
| Dec 2025 | −$32.4M | — |
| Sep 2025 | −$34.8M | — |
| 21 more quarters | Free account |
Against its own ten years
Low −$245.8M
High −$13.0M
Ten-year median
−$142.9M
Current reading's percentile
57
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| TVTX Travere Therapeutics, Inc. compare | −$83.5M |
| MANE Veradermics Incorporated compare | −$88.4M |
| DNTH Dianthus Therapeutics, Inc. compare | −$227.5M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| ERAS Erasca, Inc. | −$302.6M |
| COGT Cogent Biosciences, Inc. compare | −$388.7M |
| SRRK Scholar Rock Holding Corporation compare | −$405.8M |
| CRSP CRISPR Therapeutics AG compare | −$513.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item